Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Pediatric Rheumatology

Building Your Care Team: Advocacy and Preparation

At a Glance

Because juvenile dermatomyositis can affect muscles, skin, lungs, and bones, care is coordinated by a pediatric rheumatologist with other specialists. Families can prepare by bringing complete records, asking about progress measures, and seeking expert consultation when needed.

Because Juvenile Dermatomyositis (JDM) is a rare and multisystemic disease, your child needs more than just a single doctor. They often benefit from a multidisciplinary care team—a group of specialists who collaborate to treat every aspect of the illness, from skin and muscle to lung and bone health [1][2].

The “captain” of this team is almost always a Pediatric Rheumatologist [3]. However, even the most experienced rheumatologist will typically bring in other experts to ensure your child receives comprehensive care.

Your Child’s Multidisciplinary Team

Depending on your child’s manifestations and disease severity, the care team may include the following specialists [1][2][3]:

  • Pediatric Rheumatologist: Coordinates the overall treatment plan, monitors disease activity, and manages immunosuppressant medications.
  • Pediatric Dermatologist: Specializes in the unique rashes and skin ulcers of JDM, which can sometimes persist even after muscle strength improves [3][4].
  • Pediatric Pulmonologist: Monitors lung function (using Pulmonary Function Tests or PFTs) to catch lung inflammation early, especially in children with the anti-MDA5 antibody [5][6].
  • Physical and Occupational Therapists (PT/OT): Essential for maintaining range of motion, preventing muscle shortening (contractures), and rebuilding strength safely. Not every child needs both; it depends on their specific deficits [2][7].
  • Pediatric Psychologist/Social Worker: Helps your child and family cope with the emotional toll of a chronic illness, manages needle phobias, and assists with school accommodations [8][2].
  • Other Potential Partners: Depending on your child’s specific symptoms, the team may also include a Cardiologist, Gastroenterologist, or Endocrinologist [9][10][11].

Preparing for the First Specialist Visit

When you visit a new specialist or seek a second opinion, arriving prepared allows the doctor to spend more time examining your child and less time hunting for data [12].

Essential “Artifacts” to Bring:

  • Imaging Discs: Ask the hospital to transfer reports and images electronically or through the health-information system. If a physical device (like a CD or USB drive) is used, ensure it follows the institution’s privacy and security requirements [13][14].
  • Complete Lab History: Bring the full reports for all blood tests, including muscle enzymes (CK, Aldolase, LDH, AST, ALT) and the complete Myositis-Specific Antibody (MSA) panel [15][5].
  • Pathology Reports: If your child had a muscle or skin biopsy, bring the final report and, if possible, information on how to request the slides for a second review [16][17].
  • Medication Log: A list of every medication your child has taken for JDM, including the exact dose, the start/stop dates, and any side effects you noticed [18][19].

Evaluating a Clinician’s Expertise

JDM is so rare that it is perfectly appropriate to ask a doctor about their experience. A knowledgeable JDM team should be able to discuss:

  1. Validated Assessments: They should use standard tools like the CMAS (Childhood Myositis Assessment Scale) or MMT-8 (Manual Muscle Test) periodically to objectively track strength. The appropriate interval depends on the child and visit type [20][21].
  2. Antibody-Informed Care: They should be able to explain how your child’s specific antibody changes their monitoring plan [22][20].
  3. Treat-to-Target Goals: They should have a clear timeline for when they expect to see improvement and how they adjust care if goals aren’t met [23].

A clinician does not have to participate in a specific registry to provide competent care, but they should follow evidence-based guidelines (such as SHARE or CARRA protocols) and be willing to consult with a larger pediatric myositis center when they encounter complex issues [24]. You are your child’s most important advocate—trust your instincts and seek a second opinion if you feel the team needs more expertise [25].

Common questions in this guide

Why does a child with JDM need care from several specialists?
JDM can affect muscles, skin, lungs, bones, and overall well-being, so one clinician may not address every need. A pediatric rheumatologist usually coordinates care, while other specialists are involved according to the child's symptoms, disease severity, and test results.
Which professionals may be part of a child's JDM care team?
A pediatric rheumatologist usually leads the team, with a pediatric dermatologist, pulmonologist, physical or occupational therapist, and psychologist or social worker added as needed. Cardiology, gastroenterology, or endocrinology may also be involved when JDM affects areas they treat.
What records should I bring to my child's first JDM specialist appointment?
Bring imaging reports and images, complete blood-test results including muscle enzymes and antibody testing, and any muscle or skin biopsy reports. Also bring a medication list with doses, start and stop dates, and side effects, plus information about how to request biopsy slides if a second review is needed.
How can I tell whether a clinician has experience treating JDM?
Ask how many children with JDM the clinician and team manage and whether they use standardized strength assessments, consider antibody findings, and set clear treatment goals. A clinician does not need to belong to a particular registry, but the team should follow evidence-based guidance and be willing to consult a larger pediatric myositis center for complex cases.
What are CMAS and MMT-8 used for in JDM?
CMAS, or the Childhood Myositis Assessment Scale, and MMT-8, or the Manual Muscle Test-8, are standardized ways to measure muscle strength and physical function. Repeating these assessments over time helps the care team judge progress and whether treatment goals are being met, although the timing depends on the child's condition and type of visit.
When should I consider getting a second opinion for my child's JDM?
Because JDM is rare, a second opinion or remote consultation with a larger pediatric myositis center can be reasonable when the disease is complex or the current team has limited experience. Families can discuss this option whenever they feel additional expertise would help clarify monitoring or treatment.
Can the JDM care team help with school and emotional challenges?
Yes. A pediatric psychologist or social worker can help the child and family cope with chronic illness, address needle fears, and arrange school accommodations. Physical and occupational therapists can also support safe movement, strength, and participation in daily activities.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many children with JDM do you and your team currently manage, and do you consult with larger myositis centers for complex cases?
  2. 2.Who on your team is my primary point of contact for urgent questions, and which specific specialists do you have a direct referral relationship with?
  3. 3.What validated tools do you use periodically to measure my child's progress, such as the Childhood Myositis Assessment Scale (CMAS) or the Manual Muscle Test-8 (MMT-8)?
  4. 4.How do you typically manage 'treat-to-target' goals? If we don't meet our 6-week or 3-month milestones, what is your next-step protocol?
  5. 5.Do you have a designated social worker or psychologist who helps families navigate the emotional and school-related challenges of a chronic illness?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Multispecialty approach for improving outcomes in juvenile dermatomyositis.

    Wakiguchi H

    Journal of multidisciplinary healthcare 2019; (12()):387-394 doi:10.2147/JMDH.S171095.

    PMID: 31213823
  2. 2

    [Advances in the diagnostics and treatment of juvenile dermatomyositis].

    Georgi I, Georgi M, Haas JP

    Zeitschrift fur Rheumatologie 2024; (83(1)):41-51 doi:10.1007/s00393-023-01454-y.

    PMID: 38157051
  3. 3

    Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.

    Hinze CH, Oommen PT, Dressler F, et al.

    Pediatric rheumatology online journal 2018; (16(1)):40 doi:10.1186/s12969-018-0257-6.

    PMID: 29940960
  4. 4

    Characteristics of patients with juvenile dermatomyositis from 2001-2021 at a tertiary care center.

    Simmons E, Kazmi M, Wilson M, et al.

    Dermatology online journal 2022; (28(6)) doi:10.5070/D328659719.

    PMID: 36809089
  5. 5

    Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.

    Kobayashi I

    Children (Basel, Switzerland) 2024; (11(9)) doi:10.3390/children11091046.

    PMID: 39334579
  6. 6

    Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review.

    Abu-Rumeileh S, Marrani E, Maniscalco V, et al.

    Autoimmunity reviews 2023; (22(10)):103416 doi:10.1016/j.autrev.2023.103416.

    PMID: 37611886
  7. 7

    Promising Treatments in Juvenile Dermatomyositis.

    Yi BY, Joyce M, Gilbert R, Kim S

    Rheumatic diseases clinics of North America 2025; (51(4)):719-735 doi:10.1016/j.rdc.2025.07.012.

    PMID: 41161909
  8. 8

    Mapping the current psychology provision for children and young people with juvenile dermatomyositis.

    Livermore P, Gibson F, Mulligan K, et al.

    Rheumatology advances in practice 2021; (5(3)):rkab062 doi:10.1093/rap/rkab062.

    PMID: 34671713
  9. 9

    Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain.

    Diniz MFR, Kozu KT, Elias AM, et al.

    Clinical rheumatology 2021; (40(4)):1497-1505 doi:10.1007/s10067-020-05418-4.

    PMID: 32989504
  10. 10

    Severe Abdominal Manifestations in Juvenile Dermatomyositis.

    Besnard C, Gitiaux C, Girard M, et al.

    Journal of pediatric gastroenterology and nutrition 2020; (70(2)):247-251 doi:10.1097/MPG.0000000000002575.

    PMID: 31978027
  11. 11

    Impact of Juvenile Dermatomyositis on Growth, Puberty, Bone Mineral Density, and Body Composition in Children.

    Sudhera N, Kaur H, Pandiarajan V, Singh S

    Mediterranean journal of rheumatology 2026; (37(1)):136-145 doi:10.31138/mjr.280725.ran.

    PMID: 42100059
  12. 12

    Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

    McCann LJ, Pilkington CA, Huber AM, et al.

    Annals of the rheumatic diseases 2018; (77(2)):241-250 doi:10.1136/annrheumdis-2017-212141.

    PMID: 29084729
  13. 13

    How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic?

    Oberle EJ, Bayer ML, Chiu YE, Co DO

    Pediatric dermatology 2017; (34(1)):50-57 doi:10.1111/pde.13013.

    PMID: 27813167
  14. 14

    Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis.

    Sakurai N, Hino-Shishikura A, Nozawa T, et al.

    Modern rheumatology 2019; (29(5)):808-813 doi:10.1080/14397595.2018.1511026.

    PMID: 30092673
  15. 15

    Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

    Leung AKC, Lam JM, Alobaida S, et al.

    Current pediatric reviews 2021; (17(4)):273-287 doi:10.2174/1573396317666210426105045.

    PMID: 33902423
  16. 16

    Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology.

    Challa S, Hui M, Jakati S, et al.

    Indian journal of pathology & microbiology 2019; (62(1)):61-66 doi:10.4103/IJPM.IJPM_387_17.

    PMID: 30706861
  17. 17

    Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.

    Xia J, Jiang G, Jin T, et al.

    BMC pediatrics 2021; (21(1)):488 doi:10.1186/s12887-021-02958-9.

    PMID: 34732158
  18. 18

    Medications received by patients with juvenile dermatomyositis.

    Kishi T, Bayat N, Ward MM, et al.

    Seminars in arthritis and rheumatism 2018; (48(3)):513-522 doi:10.1016/j.semarthrit.2018.03.016.

    PMID: 29773230
  19. 19

    Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies.

    Varnier GC, Consolaro A, Cheng IL, et al.

    Rheumatology (Oxford, England) 2023; (62(SI2)):SI163-SI169 doi:10.1093/rheumatology/keac404.

    PMID: 35929784
  20. 20

    Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).

    Papadopoulou C, Feldman BM

    Pediatric rheumatology online journal 2026; (24(1)).

    PMID: 42260535
  21. 21

    Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.

    Neely J, Ardalan K, Huber A, et al.

    Pediatric rheumatology online journal 2022; (20(1)):50 doi:10.1186/s12969-022-00709-3.

    PMID: 35854378
  22. 22

    Spectrum of clinical phenotypes associated with myositis-specific and myositis-associated antibodies in juvenile idiopathic inflammatory myositis: Our experience from North India.

    Vignesh P, Basu S, Nadig PL, et al.

    Seminars in arthritis and rheumatism 2026; (78()):152972 doi:10.1016/j.semarthrit.2026.152972.

    PMID: 41887030
  23. 23

    Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.

    Ravelli A, Rosina S, MacMahon JM, et al.

    Annals of the rheumatic diseases 2025; (84(7)):1055-1067 doi:10.1016/j.ard.2025.04.024.

    PMID: 40410052
  24. 24

    Juvenile Idiopathic Inflammatory Myopathies.

    Huber AM

    Pediatric clinics of North America 2018; (65(4)):739-756 doi:10.1016/j.pcl.2018.04.006.

    PMID: 30031496
  25. 25

    The family impact of caring for a child with juvenile dermatomyositis.

    Kountz-Edwards S, Aoki C, Gannon C, et al.

    Chronic illness 2017; (13(4)):262-274 doi:10.1177/1742395317690034.

    PMID: 28133992

This page explains how families can prepare for and build a juvenile dermatomyositis care team for informational purposes only; it does not constitute medical advice. Your child's pediatric rheumatologist can tailor referrals, monitoring, and treatment to your child's needs.

Get notified when new evidence is published on Juvenile dermatomyositis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.